Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $120,000,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2017 | MULTI-AG | $33,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $541,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | TX-AG | $158,000,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | WA-AG | $9,900,000 |
Johnson & Johnson | Johnson & Johnson | False Claims Act and related | 2013 | LA-AG | $10,000,000 |
Johnson & Johnson | Johnson & Johnson | False Claims Act and related | 2011 | ID-AG | $2,000,000 |
Johnson & Johnson | Johnson & Johnson | False Claims Act and related | 2019 | IL-AG | $49,505,368 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2019 | MULTI-AG | $116,860,000 |
Johnson & Johnson | Johnson & Johnson | consumer protection violation | 2015 | CA-MULTI | $506,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2020 | WV-AG | $3,900,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $5,000,000,000 |
Johnson & Johnson | Johnson & Johnson | product safety violation | 2021 | private lawsuit-federal | $2,500,000,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2005 | private lawsuit-federal | $15,000,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2004 | private lawsuit-federal | $90,000,000 |
Johnson & Johnson | Johnson & Johnson | drug or medical equipment safety violation | 2002 | private lawsuit-federal | $45,000,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
Johnson & Johnson | Johnson & Johnson | price-fixing or anti-competitive practices | 2023 | private lawsuit-federal | $25,000,000 |
Johnson & Johnson | Johnson & Johnson | product safety violation | 2023 | private lawsuit-federal | $8,900,000,000 |
Johnson & Johnson | Johnson & Johnson | consumer protection violation | 2020 | private lawsuit-federal | $6,315,000 |
Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2024 | WA-AG | $149,500,000 |
Johnson & Johnson | Johnson & Johnson | environmental violation | 2004 | EPA | $5,000 |
Jazz Pharmaceuticals plc | Jazz Pharmaceuticals | False Claims Act and related | 2019 | DOJ_CIVIL | $57,000,000 |
Jazz Pharmaceuticals Inc. | Jazz Pharmaceuticals | off-label or unapproved promotion of medical products | 2007 | USAO | $20,000,000 |
Janssen Pharmaceuticals/Johnson & Johnson | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | NH-AG | $40,500,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | USAO | $410,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | $181,000,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2013 | MA-AG | $15,100,000 |
Janssen Pharmaceuticals, Inc. | Johnson & Johnson | product safety violation | 2022 | private lawsuit-federal | $150,000,000 |
Janssen Pharmaceuticals | Johnson & Johnson | drug or medical equipment safety violation | 2019 | private lawsuit-federal | $387,500,000 |
Janssen Pharmaceuticals | Johnson & Johnson | off-label or unapproved promotion of medical products | 2022 | WV-AG | $99,000,000 |
Janssen Pharmaceutical Products, LP, Centocor, Inc., McNeil Pharmaceutical, Inc., Ortho Biotech Products, LP and Ortho-McNeil Pharmaceutical, Inc. | Johnson & Johnson | False Claims Act and related | 2012 | KY-AG | $7,000,000 |
Janssen Pharmaceutical (SB) | Johnson & Johnson | environmental violation | 2010 | EPA | $105,000 |
Janssen Pharmaceutica Inc. | Johnson & Johnson | environmental violation | 2004 | EPA | $7,700 |
Janssen Ortho LLC and Janssen Pharmaceuticals, Inc. | Johnson & Johnson | off-label or unapproved promotion of medical products | 2014 | MT-AG | $5,900,000 |
IVAX PHARMACEUTICALS, INC. | Teva Pharmaceutical Industries | workplace safety or health violation | 2002 | OSHA | $15,120 |
IVAX PHARMACEUTICALS INC | Teva Pharmaceutical Industries | air pollution violation | 2007 | NJ-ENV | $6,000 |
IVAX Pharmaceuticals | Teva Pharmaceutical Industries | False Claims Act and related | 2009 | DOJ_CIVIL | $14,000,000 |
IVAX Pharmaceuticals | Teva Pharmaceutical Industries | False Claims Act and related | 2009 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $5,400,000 |
ISTA Pharmaceuticals, Inc. | Bausch Health | False Claims Act and related | 2013 | DOJ_CIVIL | $33,500,000 |
ISTA Pharmaceuticals, Inc. | Bausch Health | off-label or unapproved promotion of medical products | 2013 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $390,253 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $5,641 |
Intermune, Inc. | Roche | Medicare Coverage Gap Discount Program violation | 2013 | CMS | $16,215 |
InterMune Inc. | Roche | Family and Medical Leave Act | 2014 | WHD | $59,085 |
InterMune Inc. | Roche | off-label or unapproved promotion of medical products | 2006 | FDA | $36,900,000 |
InterMune Inc. | Roche | off-label or unapproved promotion of medical products | 2006 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,700,000 |
Inspire Pharmaceuticals Inc. | Merck | off-label or unapproved promotion of medical products | 2015 | USAO | $5,900,000 |
Inspire Pharmaceuticals | Merck | off-label or unapproved promotion of medical products | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $6,000,000 |
Indivior, Inc. | Indivior PLC | price-fixing or anti-competitive practices | 2020 | FTC | $10,000,000 |
Indivior Solutions | Indivior PLC | False Claims Act and related | 2020 | DOJ_CIVIL | $589,000,000 |
Indivior plc | Indivior PLC | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $300,000,000 |
Indivior Inc. | Indivior PLC | price-fixing or anti-competitive practices | 2023 | MULTI-AG | $102,500,000 |
Indivior Inc. | Indivior PLC | price-fixing or anti-competitive practices | 2023 | private lawsuit-federal | $30,000,000 |
Indivior Inc. | Indivior PLC | price-fixing or anti-competitive practices | 2024 | private lawsuit-federal | $385,000,000 |
Incyte Corporation | Incyte Corp. | False Claims Act and related | 2021 | DOJ_CIVIL | $12,600,000 |
Impax Laboratories, Inc. | Amneal Pharmaceuticals | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $15,000,000 |
Impax Laboratories, Inc. | Amneal Pharmaceuticals | price-fixing or anti-competitive practices | 2022 | private lawsuit-federal | $145,000,000 |
Impax Laboratories, Inc. | Amneal Pharmaceuticals | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $20,000,000 |
Impax Laboratories, Inc. | Amneal Pharmaceuticals | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $37,500,000 |
IMPAX LABORATORIES, INC | Amneal Pharmaceuticals | workplace safety or health violation | 2004 | OSHA | $18,000 |
IMO SANOFI PASTEUR | Sanofi | hazardous waste violation | 2014 | EPA | $77,643 |
IMMUNOMEDICS, INC. EMPLOYEES' 401(K) SAVINGS PLAN | Gilead Sciences | benefit plan administrator violation | 2001 | EBSA | $10,001 |
Immunex Corporation | Amgen | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $9,615,384 |
Immunex Corp. | Amgen | False Claims Act and related | 2009 | IA-AG | $357,000 |
Imclone Systems, Inc. | Eli Lilly | employment discrimination | 2005 | EEOC | $85,000 |
IDEXX Reference Laboratories, Inc. | IDEXX Laboratories | environmental violation | 2009 | AZ-DEQ | $80,000 |
IDEXX Laboratories, Inc. | IDEXX Laboratories | employment discrimination | 2020 | OFCCP | $200,000 |
IDEXX DISTRIBUTION, INC. | IDEXX Laboratories | workplace safety or health violation | 2017 | OSHA | $9,600 |
IDEXX DISTRIBUTION, INC. | IDEXX Laboratories | workplace safety or health violation | 2023 | OSHA | $32,245 |
ICN Pharmaceuticals, Inc. | Bausch Health | accounting fraud or deficiencies | 2002 | SEC | $1,000,000 |
ICN Pharmaceuticals, Inc. | Bausch Health | fraud | 2001 | USAO | $5,600,000 |
ICN Pharmaceuticals, Inc | Bausch Health | economic sanction violation | 2004 | OFAC | $5,500 |
HOSPIRA, INC. | Pfizer | workplace safety or health violation | 2004 | OSHA | $132,300 |
Hospira Inc. | Pfizer | employment discrimination | 2015 | OFCCP | $400,000 |
HOSPIRA | Pfizer | workplace safety or health violation | 2006 | OSHA | $6,750 |
Hoffmann-La Roche, Inc. | Roche | employment discrimination | 2012 | private lawsuit-federal | $545,833 |
Hoffmann-La Roche Inc. | Roche | price-fixing or anti-competitive practices | 2008 | private lawsuit-federal | $11,000,000 |
Hoffmann-La Roche | Roche | price-fixing or anti-competitive practices | 2000 | private lawsuit-federal | $130,000,000 |
Hoffman-LaRoche | Roche | price-fixing or anti-competitive practices | 2000 | MULTI-AG | $142,494,000 |
Hoffman-LaRoche | Roche | price-fixing or anti-competitive practices | 2000 | CA-AG | $47,498,000 |
Hoffman-LaRoche | Roche | price-fixing or anti-competitive practices | 2002 | MA-AG | $111,167 |
HOFFMAN LAROCHE INC | Roche | hazardous waste violation | 2002 | NJ-ENV | $5,000 |
Hoechst Marion Roussel, Inc. | Sanofi | price-fixing or anti-competitive practices | 2016 | private lawsuit-state | $50,000,000 |
Hoechst Marion Roussel | Sanofi | price-fixing or anti-competitive practices | 2011 | private lawsuit-federal | $9,615,384 |
Hoechst Marion Roussel | Sanofi | price-fixing or anti-competitive practices | 2003 | private lawsuit-federal | $55,000,000 |
Hoechst AG | Sanofi | price-fixing or anti-competitive practices | 2003 | DOJ_ANTITRUST | $12,000,000 |
Hoechst AG | Sanofi | price-fixing or anti-competitive practices | 2000 | private lawsuit-federal | $37,000,000 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $150,000,000 |
HIKMA PHARMACEUTICALS | Hikma Pharmaceuticals | workplace safety or health violation | 2020 | OSHA | $20,479 |
HI TECH PHARMACAL CO., INC. | Akorn Inc. | water pollution violation | 2001 | EPA | $20,500 |
GNC HOLDINGS LLC | Harbin Pharmaceutical Group | workplace safety or health violation | 2022 | OSHA | $6,720 |
GNC Holdings Inc. | Harbin Pharmaceutical Group | drug or medical equipment safety violation | 2016 | FDA | $2,250,000 |
GNC HOLDINGS INC. | Harbin Pharmaceutical Group | workplace safety or health violation | 2023 | OSHA | $17,858 |
GNC | Harbin Pharmaceutical Group | employment discrimination | 2019 | NY-NYCCHR | $35,000 |
Glenmark Pharmaceuticals, Inc. | Glenmark Pharmaceuticals | HHS civil monetary penalties | 2015 | HHSOIG | $2,887,300 |
Glenmark Pharmaceuticals Inc., USA | Glenmark Pharmaceuticals | price-fixing or anti-competitive practices | 2023 | DOJ_ANTITRUST | $30,000,000 |
Glenmark Pharmaceuticals | Glenmark Pharmaceuticals | price-fixing or anti-competitive practices | 2023 | private lawsuit-federal | $14,000,000 |
Glenmark Generics Inc. | Glenmark Pharmaceuticals | False Claims Act and related | 2015 | TX-AG | $13,750,000 |
GlaxoSmithKline, LLC | GlaxoSmithKline | drug or medical equipment safety violation | 2011 | MULTI-AG | $40,750,000 |
GlaxoSmithKline, LLC | GlaxoSmithKline | kickbacks and bribery | 2014 | MULTI-AG | $105,000,000 |
GlaxoSmithKline, LLC | GlaxoSmithKline | off-label or unapproved promotion of medical products | 2013 | MD-AG | $15,000,000 |